Package Leaflet: Information for the User
Sitagliptin/Metformin Stada 50 mg/850 mg film-coated tablets EFG
sitagliptin/metformin, hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin/Metformin Stada contains two different medicines called sitagliptin and metformin.
They work together to control the levels of sugar in your blood in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps to increase the amount of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps to lower your blood sugar levels. This medicine can be used alone or with certain other medicines for diabetes (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a disease in which your body does not produce enough insulin and the insulin your body produces does not work as well as it should. Your body may also produce too much sugar.
When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart diseases (cardiac), kidney diseases (renal), blindness, and amputations.
Do not take Sitagliptin/Metformin Stada:
Do not take sitagliptin/metformin if any of the above applies to you and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking sitagliptin/metformin.
Warnings and precautions
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin/metformin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin/metformin.
Risk of lactic acidosis
Sitagliptin/metformin may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see more information below), liver problems, and any medical condition in which a part of your body has a reduced supply of oxygen (such as acute and severe heart diseases).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking sitagliptin/metformin for a short period of time if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, exposure to heat, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop takingsitagliptin/metformin and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Consult your doctor or pharmacist before starting to take Sitagliptin/Metformin Stada:
If you need to undergo major surgery, you should stop taking sitagliptin/metformin during the procedure and for a period of time after. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can start taking it again.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking sitagliptin/metformin.
During treatment with sitagliptin/metformin, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.
Other medicines and Sitagliptin/Metformin Stada
If you need to be given an injection of a contrast agent that contains iodine, for example, in the context of an X-ray or scan, you should stop taking sitagliptin/metformin before the injection or at the time of the injection. Your doctor will decide when you should stop taking sitagliptin/metformin and when you can start taking it again.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of sitagliptin/metformin. It is especially important to mention the following:
Taking Sitagliptin/Metformin Stada with alcohol
Avoid excessive alcohol intake while taking sitagliptin/metformin, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy or while breast-feeding. See section 2, Do not take Sitagliptin/Metformin Stada.
Driving and using machines
The effect of this medicine on your ability to drive and use machines is negligible or minimal. However, there have been reports of dizziness and drowsiness during treatment with sitagliptin, which may affect your ability to drive and use machines.
Taking this medicine with the medicines called sulfonylureas or with insulin may cause low blood sugar levels (hypoglycemia), which may affect your ability to drive and use machines or work without a safe support.
Sitagliptin/Metformin Stada contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially, “sodium-free”.
Follow exactly the instructions of your doctor for taking this medicine. If you are not sure, consult your doctor or pharmacist again.
Dose
The recommended dose is one tablet twice a day.
Your doctor may need to increase the dose to control your blood sugar levels.
Method of administration
It should be taken orally with food to reduce the likelihood of stomach upset.
Kidney problems
If you have reduced kidney function, your doctor may prescribe a lower dose.
Other medicines and recommendations
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause you to have low blood sugar levels (hypoglycemia). Low blood sugar levels can occur when this medicine is taken with a medicine that contains a sulfonylurea or with insulin, so your doctor may need to reduce the dose of your sulfonylurea or insulin.
If you take more Sitagliptin/Metformin Stada than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, severe nausea or vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
If you forget to take Sitagliptin/Metformin Stada
If you forget to take a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your normal treatment schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin/Metformin Stada
Keep taking this medicine for as long as your doctor tells you to, so that it can help to control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking sitagliptin/metformin, your blood sugar levels may increase again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking sitagliptin/metformin andcontact a doctor or the nearest hospitalimmediately if you notice any of the following serious adverse effects:
Very rare(may affect up to 1 in 10,000 people):
STOP taking sitagliptin/metformin andcontact a doctorimmediately if you notice any of the following serious adverse effects:
Frequency not known(frequency cannot be estimated from available data):
Your doctor will prescribe a medicine to treat the allergic reaction and change the medicine for diabetes treatment
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptin:
Frequent(may affect up to 1 in 10 people):
Infrequent(may affect up to 1 in 100 people):
Some patients who took metformin have experienced the following adverse effects after starting treatment with thecombination of sitagliptin and metformin:
Frequent:
Some patients have experienced the following adverse effects while takingthis medicine along with a sulfonylurea such as glimepiride:
Very frequent(may affect more than 1 in 10 people):
Frequent:
Some patients have experienced the following adverse effects while takingthis medicine in combination with pioglitazone:
Frequent:
Some patients have experienced the following adverse effects while takingthis medicine in combination with insulin:
Very frequent:
Infrequent:
Some patients have experienced the following adverse effectsduring clinical trials while taking sitagliptin alone(one of the medicines that contains sitagliptin/metformin) orduring use after approval of sitagliptin/metformin or sitagliptin alone or with other diabetes medicines:
Frequent:
Infrequent:
Rare:
Frequency not known:
Some patients have experienced the following adverse effects after takingmetformin alone:
Very frequent:
These symptoms may appear when you start taking metformin and usually disappear.
Frequent:
Very rare:
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Bottles
Do not use this medicine after the expiration date shown on the bottle and packaging after CAD.
Blister packs
Do not use this medicine after the expiration date shown on the blister pack and packaging after CAD.
The expiration date is the last day of the month indicated.
Do not store above 30°C.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Sitagliptin/Metformin Stada
Tablet core: microcrystalline cellulose, povidone (K29/32), sodium lauryl sulfate, magnesium stearate.
Film coating: macrogol and poly(vinyl alcohol) graft copolymer (E1209), talc (E553b), titanium dioxide (E171), GMDCC, GMCC mono/glycerides Type 1, glycerol (E471), partially hydrolyzed polyvinyl alcohol (E1203), red iron oxide (E172).
Appearance of Sitagliptin/Metformin Stada and Package Contents
Film-coated tablet, oval-shaped, biconvex, pink, approximately 20.5 mm x 9.5 mm, and with "S476" engraved on one side.
Bottles
The film-coated tablets are packaged in a high-density polyethylene (HDPE) bottle with a polypropylene (PP) screw cap and a desiccant silica gel contained in the PP cap.
Pack sizes: 100, 196 tablets.
Blister packs
The film-coated tablets are packaged in opaque aluminum hard/PVC/PVDC blister packs.
Pack sizes: 14, 28, 30, 56, 60, 196, 210 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
info@stada.es
Manufacturer
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
or
Laboratorios Liconsa S.A.
Avenida Miralcampo 7
19200 Azuqueca De Henares
Spain
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Vienna
Austria
or
Clonmel Healthcare Limited
3 Waterford Road
E91 D768 Clonmel
Ireland
This medicine is authorized in the Member States of the European Economic Area under the following names:
Netherlands Sitagliptine/Metformine hydrochloride STADA 50 mg/850 mg filmomhulde tabletten
Austria Sitagliptin/Metformin STADA 50 mg/850 mg Filmtabletten
Czech Republic Sitagliptin/Metformin STADA
Germany Sitagliptin/Metformin STADA 50 mg/850 mg Filmtabletten
Denmark Sitagliptin/Metformin STADA
Spain Sitagliptina/Metformina STADA 50 mg/850 mg comprimidos recubiertos con película EFG
Finland Sitagliptin/Metformin STADA 50 mg/850 mg kalvopäällysteiset tabletit
Ireland Sitagliptin/Metformin Clonmel 50 mg/850 mg film-coated tablets
Iceland Sitagliptin/Metformin STADA 50 mg/850 mg filmuhúðaðar töflur
Italy Sitagliptin e Metformina EG
Portugal Metformina + Sitagliptina Ciclum
Sweden Sitagliptin/Metformin STADA 50 mg/850 mg filmdragerade tabletter
Slovenia Sitagliptin/metforminijev klorid STADA 50 mg/850 mg filmsko obložene tablete
Slovakia Sitagliptin-Metformin STADA 50mg/850mg filmom obalené tablety
Date of the last revision of this prospectus:March 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).